MX2016014483A - Nuevos compuestos utiles como inhibidores de s100. - Google Patents

Nuevos compuestos utiles como inhibidores de s100.

Info

Publication number
MX2016014483A
MX2016014483A MX2016014483A MX2016014483A MX2016014483A MX 2016014483 A MX2016014483 A MX 2016014483A MX 2016014483 A MX2016014483 A MX 2016014483A MX 2016014483 A MX2016014483 A MX 2016014483A MX 2016014483 A MX2016014483 A MX 2016014483A
Authority
MX
Mexico
Prior art keywords
inhibitors
novel compounds
compounds useful
disorders
compound
Prior art date
Application number
MX2016014483A
Other languages
English (en)
Inventor
Liberg David
East Stephen
Prevost Natacha
Wellmar Ulf
EKBLAD Maria
Bainbridge Marie
Hargrave Jonathan
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of MX2016014483A publication Critical patent/MX2016014483A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)

Abstract

La presente invención se refiere a un compuesto de la fórmula (I) o a una sal del mismo farmacéuticamente aceptable y a una composición farmacéutica que comprende el compuesto. El compuesto es un inhibidor de las interacciones entre S100A9 y los copartícipes de interacción tales como RAGF, TLR4 y EMMPRIN y como tal es útil en el tratamiento de los trastornos tales como el cáncer, trastornos autoinmunes, trastornos inflamatorios y trastornos neurodegenerativos.
MX2016014483A 2014-05-23 2015-05-22 Nuevos compuestos utiles como inhibidores de s100. MX2016014483A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14169757 2014-05-23
PCT/EP2015/061468 WO2015177367A1 (en) 2014-05-23 2015-05-22 Novel compounds useful as s100-inhibitors

Publications (1)

Publication Number Publication Date
MX2016014483A true MX2016014483A (es) 2017-01-23

Family

ID=50774707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014483A MX2016014483A (es) 2014-05-23 2015-05-22 Nuevos compuestos utiles como inhibidores de s100.

Country Status (13)

Country Link
US (1) US9771372B2 (es)
EP (1) EP2991990B1 (es)
JP (1) JP6580074B2 (es)
KR (1) KR20170005868A (es)
CN (1) CN106414448B (es)
AU (1) AU2015261775B2 (es)
BR (1) BR112016024749A2 (es)
CA (1) CA2948436A1 (es)
EA (1) EA030604B1 (es)
ES (1) ES2620751T3 (es)
HK (1) HK1221463A1 (es)
MX (1) MX2016014483A (es)
WO (1) WO2015177367A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7392951B2 (ja) 2018-04-27 2023-12-06 国立大学法人 岡山大学 抗ｓ１００ａ８／ａ９抗体とその用途
US11197908B2 (en) 2018-07-17 2021-12-14 The Board Of Trustees Of The University Of Arkansas Peptoids and methods for attenuating inflammatory response
EP4052725A4 (en) 2019-10-30 2024-07-17 Nat Univ Corporation Okayama Univ PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR INFLAMMATORY LUNG DISEASE
WO2023209141A1 (en) 2022-04-29 2023-11-02 Westfälische Wilhelms-Universität Münster Benzo[d]imidazo[1,2-a]imidazoles and their use in diagnosis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
AR029489A1 (es) 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
AU2001289749B9 (en) 2000-07-26 2004-08-19 Smithkline Beecham P.L.C. Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
EP1387680A4 (en) * 2001-03-05 2010-01-13 Transtech Pharma Inc AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE
GB0117506D0 (en) 2001-07-18 2001-09-12 Bayer Ag Imidazopyridinones
SE0104331D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Novel compounds
EP2324830A1 (en) * 2002-03-05 2011-05-25 TransTech Pharma Inc. Process for the preparation of a monocyclic azole derivative that inhibits the interaction of ligands with rage
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
AU2007305399B2 (en) 2006-09-28 2013-09-26 Exelixis, Inc. JAK-2 Modulators and Methods of Use
WO2008118454A2 (en) 2007-03-23 2008-10-02 Amgen Inc. Derivatives of quinoline or benzopyrazine and their uses for the treatment of (inter alia) inflammatory diseases, autoimmune diseases or various kinds of cancer
EP1986009A1 (en) * 2007-04-26 2008-10-29 Active Biotech AB Screening method
EP2170072A4 (en) 2007-06-13 2010-10-27 Glaxosmithkline Llc Farnesoid X RECEPTOR AGONISTS
AU2009206936A1 (en) * 2008-01-22 2009-07-30 Takeda Pharmaceutical Company Limited Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them
TW201004941A (en) 2008-07-16 2010-02-01 Wyeth Corp Alpha7 nicotinic acetylcholine receptor inhibitors
KR20110128908A (ko) 2009-03-02 2011-11-30 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 8-치환된 퀴놀린 및 관련 유사체
ES2552514T3 (es) 2011-11-03 2015-11-30 Hoffmann-La Roche Ag Compuestos bicíclicos de piperazina
GB201321728D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents

Also Published As

Publication number Publication date
US20170204098A1 (en) 2017-07-20
AU2015261775B2 (en) 2019-07-11
EA030604B1 (ru) 2018-08-31
CA2948436A1 (en) 2015-11-26
CN106414448A (zh) 2017-02-15
HK1221463A1 (zh) 2017-06-02
ES2620751T3 (es) 2017-06-29
JP6580074B2 (ja) 2019-09-25
KR20170005868A (ko) 2017-01-16
JP2017516772A (ja) 2017-06-22
AU2015261775A1 (en) 2016-12-08
US9771372B2 (en) 2017-09-26
BR112016024749A2 (pt) 2017-08-15
WO2015177367A1 (en) 2015-11-26
EP2991990B1 (en) 2017-02-01
CN106414448B (zh) 2019-04-19
EP2991990A1 (en) 2016-03-09
EA201692405A1 (ru) 2017-06-30

Similar Documents

Publication Publication Date Title
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
EA201790528A1 (ru) Дигидропирролопиридиновые ингибиторы ror-гамма
PH12016501457A1 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
PH12016500330B1 (en) Certain chemical entities, compositions, and methods
PH12016500024A1 (en) Bromodomain inhibitor
EP4230264A3 (en) Prodrugs of fumarates and their use in treating various deseases
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
WO2014179564A8 (en) Thiazolopyrrolidine inhibitors of ror-gamma
EA201691421A1 (ru) Гетероарилы и их применение
PH12016501702B1 (en) Pyrazole amide derivative
EA201591509A1 (ru) Ингибиторы cdc7
WO2015054642A3 (en) Use of cbp/ep300 bromodomain inhibitors for cancer immunotherapy
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
CL2018000565A1 (es) Compuestos derivados de piridinona dicarboxamida, inhibidores de bromodominio; composicion farmaceutica; combinacion farmaceutica; utiles en el tratamiento de enfermedades autoinmunitarias, inflamatorias, virales y cancer, entre otras.
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
PH12017500348B1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
MX2015017035A (es) Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
EA201890364A1 (ru) СОЕДИНЕНИЯ, ПРИГОДНЫЕ ДЛЯ ИНГИБИРОВАНИЯ ROR-ГАММА-t
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
MX2016014483A (es) Nuevos compuestos utiles como inhibidores de s100.
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
MX2015015741A (es) Derivados de n-(heteroaril)-sulfonamida utiles como inhibidores de s100.